Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Auayporn Nadamanee"'
Autor:
Ramón García-Sanz, Juan Pinelli, Angelo Michele Carella, Amanda F. Cashen, Veronika Bachanova, Jeffrey Matous, Andy I. Chen, Auayporn Nadamanee, Dirk Huebner, Sally Arai, Edward Agura, Emily K. Larsen
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S46
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Jerzy Holowiecki, Dzhelil Osmanov, Craig H. Moskowitz, John W. Sweetenham, Angelo Michele Carella, Alessandro Gianni, Patrick J. Stiff, Andy I. Chen, Jan Walewski, Yin Yang, Tamas Masszi, Dirk Huebner, Edward Agura, Auayporn Nadamanee, Naomi N. H. Hunder, Anna Sureda, Muneer H. Abidi
Publikováno v:
Biology of Blood and Marrow Transplantation. 20(2):S115-S116
Autor:
Dirk Huebner, Craig H. Moskowitz, Patrick J. Stiff, Jerzy Holowiecki, Andy I. Chen, Dzhelil Osmanov, Auayporn Nadamanee, Veronika Bachanova, Tamas Masszi, Emily K. Larsen, Muneer H. Abidi, John W. Sweetenham, Naomi N. H. Hunder, Anna Sureda, Jan Walewski, Alessandro M. Gianni, Angelo Michele Carella, Edward Agura
Publikováno v:
Blood. 124:673-673
Background For the past 20 years, high-dose therapy plus autologous stem cell transplant (ASCT) has been the standard of care for patients (pts) with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), providing a cure for approximately 50% of
Autor:
Jasmine Zain, S.J. Forman, Nicole Tsai, Joycelynne Palmer, Auayporn Nadamanee, Aparna Krishnan, Leslie Popplewell, Ryotaro Nakamura, Mark Kirschbaum, Roberto Rodriguez
Publikováno v:
Blood. 108:3026-3026
Background: T cell NHL represent approximately 10–15% of all lymphomas. Pts with T cell NHL are often treated similarly to patient with B cell NHL, although the clinical outcomes of most patients with T- NHL tend to be worse with the exception of A